ESTA
Establishment Labs Holdings Inc.
ESTA has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
ESTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
ESTA's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ESTA PE Valuation
ESTA has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ESTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ESTA has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ESTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.26 | +$1.60 |
| Q2 2026 | -$1.29 | +$1.78 |
| Q1 2026 | -$1.47 | +$1.65 |
| Q4 2025 | -$1.72 | +$1.28 |
| Q3 2025 | -$2.86 | -$0.25 |
| Q2 2025 | -$3.07 | +$0.07 |
| Q1 2025 | -$3.12 | +$0.05 |
| Q4 2024 | -$3.00 | +$0.07 |
ESTA is still losing money, but far less than before: $1.26 per share over the past year, against $3.32 at its worst in early 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ESTA on earnings quality, reporting a profit while its opponent remains loss making.
ESTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | +34% |
| Q2 2026 | $67.5M | +32% |
| Q1 2026 | $59.9M | +45% |
| Q4 2025 | $64.6M | +45% |
| Q3 2025 | $53.8M | +34% |
| Q2 2025 | $51.3M | +16% |
| Q1 2025 | $41.4M | +11% |
| Q4 2024 | $44.5M | +41% |
ESTA has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +3.8 points |
| Q2 2026 | -6.3% | +21 points |
| Q1 2026 | -11% | +30 points |
| Q4 2025 | -6.1% | +36 points |
| Q3 2025 | -7.5% | +25 points |
| Q2 2025 | -28% | -6.3 points |
| Q1 2025 | -41% | -17 points |
| Q4 2024 | -42% | +28 points |
ESTA's operating margin was −3.6% last quarter, up 3.8 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ESTA on profitability, with a higher operating margin.
ESTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.8M | +$19.9M |
| Q2 2026 | -$20.3M | +$117K |
| Q1 2026 | -$6.2M | +$15.3M |
| Q4 2025 | -$2M | +$19.3M |
| Q3 2025 | -$13.1M | +$836K |
| Q2 2025 | -$20.4M | -$5.4M |
| Q1 2025 | -$21.5M | -$7M |
| Q4 2024 | -$21.3M | -$12.5M |
ESTA has burned cash in almost every quarter: −$22M over the past year, against −$76M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ESTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ESTA Net Leverage
ESTA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ESTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.1 | Neutral |
| Stochastic | 32.4 | Neutral |
ESTA's weekly RSI is 48 (neutral) and its Stochastic is 32 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ESTA PE vs Healthcare Sector
ESTA has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ESTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $64.1 | 7.1% above |
| 20 week MA | $74.1 | 7.4% below |
| 50 week MA | $71.9 | 4.6% below |
| 100 week MA | $56.5 | 22% above |
| 200 week MA | $53.3 | 29% above |
ESTA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ESTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.1 | $35.0 | +29% |
| 2021 | $35.0 | $63.5 | +81% |
| 2022 | $63.5 | $63.0 | -0.8% |
| 2023 | $63.0 | $25.9 | -59% |
| 2024 | $25.9 | $45.9 | +77% |
| 2025 | $45.9 | $76.5 | +66% |
| 2026 YTD | $76.5 | $68.6 | -10% |
ESTA has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.